id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0082-0007,FDA,FDA-2004-E-0082,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to Sanofi-Aventis U.S., LLC",Rule,Certificate Extending Patent Term,2007-04-20T04:00:00Z,2007,4,,,2025-11-19T00:00:42Z,,0,0,090000648046ede0
FDA-2004-E-0082-0006,FDA,FDA-2004-E-0082,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2007-01-11T05:00:00Z,2007,1,,,2025-11-18T23:59:11Z,,0,0,090000648046eddf
FDA-2004-E-0082-0005,FDA,FDA-2004-E-0082,Determination of Regulatory Review Period for Purposes of Patent Extension; UROXATRAL,Notice,General Notice,2006-07-25T04:00:00Z,2006,7,2006-06-13T04:00:00Z,,2025-11-18T23:55:43Z,E6-9201,0,0,090000648046edde
FDA-2004-E-0082-0003,FDA,FDA-2004-E-0082,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-18T23:49:14Z,,0,0,090000648046eddb
FDA-2004-E-0082-0004,FDA,FDA-2004-E-0082,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-18T23:51:51Z,,0,0,090000648046eddc
FDA-2004-E-0082-0002,FDA,FDA-2004-E-0082,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-10-22T04:00:00Z,2004,10,,,2025-11-18T23:45:53Z,,0,0,090000648046edda
FDA-2004-E-0082-0001,FDA,FDA-2004-E-0082,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-09-02T04:00:00Z,2004,9,,,2025-11-18T23:43:41Z,,0,0,090000648046edd3